These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 16872287)
1. Can gene delivery close the door to HIV-1 entry after escape? Swan CH; Torbett BE J Med Primatol; 2006 Aug; 35(4-5):236-47. PubMed ID: 16872287 [TBL] [Abstract][Full Text] [Related]
2. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals. Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865 [TBL] [Abstract][Full Text] [Related]
3. [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications]. Azevedo-Pereira JM; Santos-Costa Q Acta Med Port; 2008; 21(5):497-504. PubMed ID: 19187693 [TBL] [Abstract][Full Text] [Related]
4. Primary SIVsm isolates use the CCR5 coreceptor from sooty mangabeys naturally infected in west Africa: a comparison of coreceptor usage of primary SIVsm, HIV-2, and SIVmac. Chen Z; Gettie A; Ho DD; Marx PA Virology; 1998 Jun; 246(1):113-24. PubMed ID: 9656999 [TBL] [Abstract][Full Text] [Related]
5. Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy. Bai J; Rossi J; Akkina R AIDS Res Hum Retroviruses; 2001 Mar; 17(5):385-99. PubMed ID: 11282007 [TBL] [Abstract][Full Text] [Related]
6. Genotypic coreceptor analysis. Sierra S; Kaiser R; Thielen A; Lengauer T Eur J Med Res; 2007 Oct; 12(9):453-62. PubMed ID: 17933727 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4. Zhou N; Fang J; Mukhtar M; Acheampong E; Pomerantz RJ Gene Ther; 2004 Dec; 11(23):1703-12. PubMed ID: 15306840 [TBL] [Abstract][Full Text] [Related]
8. Prospects of HIV-1 entry inhibitors as novel therapeutics. Pierson TC; Doms RW; Pöhlmann S Rev Med Virol; 2004; 14(4):255-70. PubMed ID: 15248253 [TBL] [Abstract][Full Text] [Related]
9. Targeting chemokine receptors in HIV: a status report. Kuhmann SE; Hartley O Annu Rev Pharmacol Toxicol; 2008; 48():425-61. PubMed ID: 17937593 [TBL] [Abstract][Full Text] [Related]
10. Coreceptor usage by HIV-1 and HIV-2 primary isolates: the relevance of CCR8 chemokine receptor as an alternative coreceptor. Calado M; Matoso P; Santos-Costa Q; Espirito-Santo M; Machado J; Rosado L; Antunes F; Mansinho K; Lopes MM; Maltez F; Santos-Ferreira MO; Azevedo-Pereira JM Virology; 2010 Dec; 408(2):174-82. PubMed ID: 20947116 [TBL] [Abstract][Full Text] [Related]
11. HIV chemokine receptor inhibitors as novel anti-HIV drugs. Princen K; Schols D Cytokine Growth Factor Rev; 2005 Dec; 16(6):659-77. PubMed ID: 16005254 [TBL] [Abstract][Full Text] [Related]
12. Pouncing on the chemokine receptor Chimera. Mascolini M J Int Assoc Physicians AIDS Care; 1997 Aug; 3(8):13-24. PubMed ID: 11364629 [TBL] [Abstract][Full Text] [Related]
13. Gene silencing of HIV chemokine receptors using ribozymes and single-stranded antisense RNA. Qureshi A; Zheng R; Parlett T; Shi X; Balaraman P; Cheloufi S; Murphy B; Guntermann C; Eagles P Biochem J; 2006 Mar; 394(Pt 2):511-8. PubMed ID: 16293105 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of CCR5-dependent HIV-1 infection by hairpin ribozyme gene therapy against CC-chemokine receptor 5. Feng Y; Leavitt M; Tritz R; Duarte E; Kang D; Mamounas M; Gilles P; Wong-Staal F; Kennedy S; Merson J; Yu M; Barber JR Virology; 2000 Oct; 276(2):271-8. PubMed ID: 11040119 [TBL] [Abstract][Full Text] [Related]
15. Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo. Bai J; Gorantla S; Banda N; Cagnon L; Rossi J; Akkina R Mol Ther; 2000 Mar; 1(3):244-54. PubMed ID: 10933940 [TBL] [Abstract][Full Text] [Related]
16. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Wilkin TJ; Su Z; Kuritzkes DR; Hughes M; Flexner C; Gross R; Coakley E; Greaves W; Godfrey C; Skolnik PR; Timpone J; Rodriguez B; Gulick RM Clin Infect Dis; 2007 Feb; 44(4):591-5. PubMed ID: 17243065 [TBL] [Abstract][Full Text] [Related]
17. Determination of co-receptor usage of HIV-1. Schuitemaker H; Kootstra NA Methods Mol Biol; 2005; 304():327-32. PubMed ID: 16061986 [TBL] [Abstract][Full Text] [Related]
18. Chemokine receptors and mechanisms of cell death in HIV neuropathogenesis. Gabuzda D; Wang J J Neurovirol; 2000 May; 6 Suppl 1():S24-32. PubMed ID: 10871762 [TBL] [Abstract][Full Text] [Related]
19. Cell-Delivered Entry Inhibitors for HIV-1: CCR5 Downregulation and Blocking Virus/Membrane Fusion in Defending the Host Cell Population. Symonds G; Bartlett JS; Kiem HP; Tsie M; Breton L AIDS Patient Care STDS; 2016 Dec; 30(12):545-550. PubMed ID: 27905841 [TBL] [Abstract][Full Text] [Related]
20. Emergence, dominance, and possible decline of CXCR4 chemokine receptor usage during the course of HIV infection. Meehan CJ; Hedge JA; Robertson DL; McCormack GP; Travers SA J Med Virol; 2010 Dec; 82(12):2004-12. PubMed ID: 20981786 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]